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Background: The ability to deliver a gene of interest into a specific cell type is an essential aspect of biomedical
research. Viruses can be a useful tool for this delivery, particularly in difficult to transfect cell types. Adeno-
associated virus (AAV) is a useful gene transfer vector because of its ability to mediate efficient gene transduction in
numerous dividing and quiescent cell types, without inducing any known pathogenicity. There are now a number
of natural for that designed AAV serotypes that each has a differential ability to infect a variety of cell types.
Although transduction studies have been completed, the bulk of the studies have been done in vivo, and there has
never been a comprehensive study of transduction ex vivo/in vitro.
Methods: Each cell type was infected with each serotype at a multiplicity of infection of 100,000 viral genomes/cell
and transduction was analyzed by flow cytometry + .
Results: We found that AAV1 and AAV6 have the greatest ability to transduce a wide range of cell types, however,
for particular cell types, there are specific serotypes that provide optimal transduction.
Conclusions: In this work, we describe the transduction efficiency of ten different AAV serotypes in thirty-four
different mammalian cell lines and primary cell types. Although these results may not be universal due to
numerous factors such as, culture conditions and/ or cell growth rates and cell heterogeneity, these results provide
an important and unique resource for investigators who use AAV as an ex vivo gene delivery vector or who work
with cells that are difficult to transfect.
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A fundamental technique in biomedical research is to
deliver a gene of interest (transgene) into a cell in order
to alter its behavior. While transgene delivery can be
achieved by a number of different transfection strategies,
such as chemical, lipid, or electroporation based methods,
there are many cell types that are not efficiently* Correspondence: mporteus@stanford.edu
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reproduction in any medium, provided the ortransfected in these ways (for example primary T-cells,
cardiomyocytes, and primary hematopoietic stem cells).
Viral vectors have become an important resource to over-
come these barriers to gene transfer. There are a number
of different viral vectors that have been used for gene
transfer, including retroviruses, lentiviruses, and adeno-
virus, but one of the most utilized viral vectors has been
recombinant adeno-associated virus (AAV). While AAV
serotype 2 (AAV2) has been the most widely used
AAV vector, there are now multiple natural and designed
AAV capsid variants, each of which has a different tropism. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ful vector for gene transfer in a wide range of cell types.
AAV is a small, non-enveloped virus that packages
both negative and positive polarity single-stranded DNA.
AAV is a member of the Parvoviridae family and re-
quires a helper virus, such as adenovirus or herpesvirus,
for a productive infection. The wild-type genome is
4.7 kb and contains two major open reading frames
(ORFs) that include the Rep gene and Cap gene. In
addition, a third ORF was recently shown to exist [3].
When AAV is used as a gene transfer vector, the
endogenous genes are removed and replaced by an
expression cassette for the gene of interest. One of the
barriers to efficient expression of the transgene is the
conversion of the single-strand AAV (ssAAV) genome
into a duplexed single DNA molecule [4]. The limitation
in transgene expression from ssAAV vectors has been
improved by the development of self-complementary
AAV (scAAV) vectors in which the single-stranded AAV
genome self-hybridizes to form duplex DNA (Figure 1).
scAAV vectors have shown earlier onset of transgene ex-
pression and overall higher transduction efficiencies than
ssAAV vectors [4,5].
The ability to transduce different cell types is primarily
determined by the AAV protein capsid [1]. The different
capsids bind to different cellular receptors and this bind-
ing mediates entry into the cell. The primary receptor
for AAV2 and AAV3 is heparan sulfate-proteoglycan [6].
Integrin α5β5, integrin α5β1, hepatocyte growth factor
receptor (c-Met), and CD9 have also been described pre-
viously as potential co-receptors for AAV2 [7-10]. The
fibroblast growth factor receptor-1 is a co-receptor for
both AAV2 and AAV3 [11] and the 37/67-kDa laminin
receptor is a co-receptor for AAV2, AAV3, AAV8 and
AAV9 [12,13]. The primary receptor for AAV1, AAV4,
and AAV5 is O-linked sialic acid, while the primary re-
ceptor for AAV6 is N-linked sialic acid [14-17]. TheCMV
poly A
eGFP
Figure 1 A schematic representation of the self-complimentary
AAV (scAAV) genome. We constructed a scAAV genome (double
black lines) that included an eGFP reporter gene (in green) driven by
the CMV promoter (black arrow) that allowed for efficient and
quantitative analysis of transduction. This construct also included a
poly A sequence (black line) and inverted terminal repeats (ITRs)
in blue)).platelet derived growth factor receptor is a co-receptor
for AAV5 [18]. The consequence of the different cellular
receptors for capsid binding is that each of these natural
AAV serotypes transduces a different range of cell types.
The ability of different AAV serotypes to transduce dif-
ferent cell types has been previously reported, but most
of these studies have been done in vivo, and they report
on the effectiveness of tissue type transduction rather
than cell type transduction [2]. For example, a broad
study of AAV serotypes 1-9 has been done in mice [19].
However, a complete ex vivo/in vitro study of transduc-
tion efficiency is lacking. In this work, we performed an
extensive survey where thirty-four different mammalian
cell types were transduced with ten different AAV sero-
types ex vivo/in vitro. This collective data provides an
important and unique resource to the researchers inter-
ested in gene delivery ex vivo and in cultured cell lines.
Our data clearly demonstrate that there are clear quali-
tative differences for the ability of different serotypes to
transduce different sub-types giving general guidance on
the best serotypes to use and that a priori prediction is
not always possible. Transduction variability could be
high, particularly when the infection efficiency is low,
and suggest that the data should be generally viewed in
7 broad categories: 1: 0%, 2: >0-1%, 3: 1-10%, 4: 10-30%,
5: 30-60%, 6: 60-80%, 7: 80-100%. Moreover, these cat-
egories should not be viewed as rigid as it is likely that
transduction of 8%, for example, is not necessarily
different than 12%.
Results and discussion
To analyze the tropism of nine different natural AAV se-
rotypes (1-9) and one engineered serotype (1.3) (a hybrid
of AAV1 and AAV6), we used scAAV vectors that
expressed eGFP from the CMV promoter (Figure 1).
Even though ssAAV has a larger cloning capacity than
scAAV, we chose scAAV because of the overall improved
transgene expression of its vectors compared to ssAAV
vectors as this report was intended to be a straightfor-
ward capsid comparison. Because some cells have been
reported to be refractory to AAV transduction, we
wanted to use the most efficient genome technology
helping to reduce the possibility that timing and amount
of transgene expression would bias the results. We
selected eGFP as a transgene because of the ease of
quantitating transgene product fluorescence by flow
cytometry and because live cultures could be analyzed
by microscopy. We infected all cell lines at a constant
multiplicity of infection [MOI (defined here as vector
genomes per cell)] of 100,000 vector genomes/cell and
analyzed for eGFP expression two days after infection.
Furthermore, we repeated the infections at an MOI of
10,000 and saw the same trends, though a lower per-
centage of GFP + cells (data not shown). Although,
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considered high, MOIs of 10,000 and up to 500,000 have
been used for gene targeting [20,21], and importantly, it
ensures that if a cell was not transduced it was not
because too low of an MOI was tested. The results are
presented as heat-maps; higher transduction efficiencies
(measured as %GFP + cells) are displayed in red, and
lower transduction efficiencies are in blue. The actual
transduction efficiency is given as a percentage. A
complete list of the cells transduced in both Figures 2
and 3 are presented in Table 1 and a description of the
isolation of the primary cells are listed in the Materials
and Methods section.
Transduction of human primary cells
We evaluated ten different AAV serotypes for their
ability to transduce six different purified primary human
cell types: BJ fibroblasts, BJ hTERT fibroblasts, em-
bryonic stem cells (ES), human umbilical cord vein
endothelial cells (HUVEC), human keratinocytes, and
human hematopoietic progenitor cells (Figure 2a). To
avoid heterologous mixtures of cells, the primary cellA
B
Figure 2 scAAV transduction of human primary and immortalized cel
transduced with eGFP scAAV at a multiplicity of infection (MOI) of 100,000
48 hours post-infection for the percentage that were GFP positive. The num
serotype. * = Transduction less than 0.01% but greater than 0.0%.types were either isolated, as described previously (see
Materials and Methods), or purchased as purified cells.
At 48 hours post infection, we found based on %GFP +
cells, that AAV1, 2 and 6 best transduced human fibro-
blasts, AAV3 was most efficient for human ES cells,
AAV1, 1.3, 2, and 6 showed the highest transduction for
HUVECs, and AAV1, 1.3 and 6 best transduced
keratinocytes. We found none of these serotypes effi-
ciently transduced human hematopoietic progenitor cells
(purified CD34+ cells). We note the BJ fibroblasts, BJ
hTERT fibroblasts, ES cells, and HUVEC cells are not
freshly isolated cells. However, we categorize them as
primary cells here because they are not transformed and
show the same properties as freshly isolated cells.
Transduction of human cell lines
In Figure 2b, we report our results for the transduction
of twelve different human derived cell lines 48 hours
post infection based on %GFP+. We found that Caco-2
(an epithelial colorectal cell type) and K562 cells
(a hematopoietic derived cell line) were not efficiently
transduced by any of the AAV serotypes, although 20%ls. A) Human primary cells and B) human immortalized cell lines were
viral genomes (vg)/ cell. The cells were analyzed by flow cytometry at
ber in the box is the actual percentage of GFP positive cells with that
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GFP + using AAV2. The lack of transduction of K562
cells cannot be explained by the lack of expression from
a CMV promoter, as strong CMV mediated transgene
expression is obtained after transfection of K562 cells
(data not shown). All of the remaining cell types were
transduced to at least 11%, and most were transduced at
much higher efficiencies. Overall, AAV1 and AAV6 were
two of the best serotypes for efficient transduction of
human cell lines, while AAV2 and AAV3 were also
broadly effective in transduction of human cell lines
(Figure 2b).
Transduction of murine primary cells
We transduced nine different primary murine cell types
(adult skin fibroblasts, astrocytes, ES cells, hematopoietic
progenitors, keratinocytes, mesenchymal stem cells,
murine embryonic fibroblasts (MEF), skeletal muscle
progenitor, and white adipose progenitor cells) with the
ten different AAV serotypes. We also transduced two
different primary murine cell types (murine lung epithe-
lial and lung mesenchymal cells) with AAV6. We then
evaluated %GFP + at 48 hours post infection (Figure 3a).
All of these murine primary cells were either isolated, as
described previously (see Materials and Methods), orA
B
Figure 3 scAAV transduction of murine primary cells and murine, ham
B) murine, hamster, and monkey immortalized cell lines were transduced w
The cells were analyzed by flow cytometry at 48 hours post-infection for th
actual percentage of GFP positive cells with that serotype.purchased as purified cells, avoiding heterologous mix-
tures of cells. We found that none of the serotypes effi-
ciently transduced mesenchymal stem cells or skeletal
muscle progenitors. We showed that AAV6 was the best
serotype for transducing hematopoietic progenitor cells,
but only to a level of 10%, a relatively low percentage
(Figure 3a, row 4). In contrast to most other cell types
tested, we found that AAV4 infects white adipose pro-
genitor cells exceptionally well, especially in comparison
to all other serotypes (Figure 3a, row 11). We saw that
murine ES cells transduce well with AAV1 (Figure 3a,
row 3, 25%). This also fits with the data the McWhir
group showed using AAV2, 4, and 5 that mES cells were
not transduced efficiently [22]. For the remaining cell
types, at least one AAV serotype was efficient in mediat-
ing transduction. In general, AAV1 and AAV6 were two
of the best serotypes for transduction of mouse primary
cells under the conditions tested.
Transduction of monkey, hamster, and mouse cell lines
We transduced five different mammalian cell lines, in-
cluding murine 3 T3 cells, murine C2C12 cells, murine
MIN6 cells, Chinese hamster ovary cells (CHO), and
monkey COS-7 cells with the ten different AAV sero-
types and evaluated %GFP + at 48 hours post infectionster, and monkey immortalized cells. A) Murine primary cells and
ith eGFP scAAV at a multiplicity of infection (MOI) of 100,000 vg/ cell.
e percentage that were GFP positive. The number in the box is the
Table 1 Cell types and description
Human Primary Cells Description
BJ Fibroblasts Foreskin fibroblasts
BJ hTERT Fibroblasts Foreskin fibroblasts retrovirally infected with hTERT
ES cell Embryonic stem cells
HUVEC Human umbilical cord vein endothelial cells
Karatinocytes Keratinocytes
Hematopoietic Progenitor CD34+ umbilical cord cells
Human Cell Lines Description
CaCo-2 Epithelial colorectal adenocarcinoma cells
HBEC Human bronchial epithelial cells
HEK 293 Human embryonic kidney cells
HeLa Cervical cancer cells
HepG2 Hepatocellular carcinoma
HT29 Colon adenocarcinoma grade II cells
Jurkat immortalized line of T lymphocyte cells
K562 Myelogenous leukemia cells




Mouse Primary Cells Description
Adult Skin Fibroblast Murine adult skin fibroblasts (MAFs)
Astrocytes Astrocytes
ES cell Embryonic stem cells
Hematopoietic Progenitor cKit+, Sca+, Lin- hematopoietic cells
Keratinocytes Keratinocytes
Lung Epithelial Epithelial cells
Lung Mesenchymal Mesenchymal cells
Mesenchymal Stem Cells Mesenchymal stem cells
Embryonic Fibroblast Murine embryonic fibroblasts (MEFs)
Skeletal Muscle Progenitor Skeletal muscle progenitor cells
White Adipose Progenitor White adipose progenitor cells
Mouse Cell Lines Description
3 T3 Heterogeneous embryonic mouse cells
C2C12 Myoblast cells
MIN6 Pancreatic beta cells
Other Cell Lines Description
CHO Chinese hamster ovary cells
COS-7 African green monkey kidney fibroblasts
Listed are the cell types transduced by AAV1-9 and AAV1.3 in Figures 2 and 3. The Materials and Methods section list a more detailed description of the primary
cell isolations.
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serotype that transduced cells with >50% transduction
efficiency (Figure 3b). In some cases our results did not
match perfectly with previous results [23] (for example
AAV1, AAV2, AAV5 on C2C12 cells; AAV1, AAV2,
AAV5 on CHOK1 cells). With the exception of AAV5on C2C12 cells, the data presented here reasonably
reflect previous data [23] when viewing the panel quali-
tatively, and the differences in culture conditions and
MOI (10,000 or 100,000 vs. 300 vg/cell) could account
for the variability. Another discrepancy from our data
[24] showed that AAV2 transduced COS cells better
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possibly be explained by changes in viral preparation,
culture conditions, and the detection system used (hFIX
expression vs. GFP expression). Overall, we found that
AAV1 and AAV6 are two of the best serotypes to infect
cell lines of mouse, hamster, and monkey origin under
the conditions tested; however, the particular cell type
must be considered, as other serotypes were more
efficient in some cases.Conclusion
Expansion in the number of AAV serotypes, both
through the identification of novel natural serotypes and
new, engineered serotypes [16,23,25-35], has resulted in
improved gene transfer to specific cell types in vivo.
There have been several publications reviewing the
preferred in vivo tropism of these new serotypes [2,36].
However ex vivo/in vitro data is lacking. Alternative uses
of AAV include using this viral vector ex vivo as a
method of gene transfer into specific cell types. These
transduced cells could then be studied directly or used
for cell-based gene therapy, whereby AAV transduction
would occur and the modified cells would then be
transplanted.
Another potential use of AAV vector transduction
ex vivo would be to use AAV vectors to stimulate gene
targeting by homologous recombination, to precisely
modify the genome of the cells to be transplanted. This
modification could be done through gene targeting
directly by AAV [37-40] or in combination with the
induction of a site-specific double-strand break. These
site-specific double-strand breaks could be induced by a
homing endonuclease [21,41,42], by zinc finger nucle-
ases [43], or by some other nuclease, like TAL effector
nucleases (TALENs) [44-47]. An important aspect to
using AAV in this manner is to determine the best
serotype to transduce specific cell types ex vivo, where
there is no basement membrane or extracellular matrix.
In fact, we have already reported the ability of a single
AAV6 vector to deliver both zinc-finger nucleases as
well as a donor repair substrate, to stimulate gene
targeting [20].
In regards to stem cells, it is intriguing that many pro-
genitor cells did not transduce well (i.e. see lots of dark
blue in the heat maps). Perhaps the cells have evolved
the ability to avoid transduction as a way to protect
themselves from changes to the cell, in particular the
DNA. However, there certainly were stem cells that were
transduced well by various AAV serotypes. This again
points to the utility of this study, as certain serotypes
were good for transduction in some stem cells and bad
in others and although AAV1 and AAV6 were good or
the best at transduction in many stem cells, there weresome stem cells that transduced poorly with AAV1 and
AAV6.
In this work we provide a broad survey that examines
the ability of ten different AAV serotypes to infect thirty-
four different cell types ex vivo/in vitro. In general, we
demonstrate that AAV1 and AAV6 have the greatest
ability to transduce a wide range of cell types. We found,
however, that for particular cell types there are specific
serotypes, which provide optimal transduction. (For ex-
ample, AAV4 is the optimal serotype for transducing
murine adipose progenitor cells.) We also found that
there are certain primary cell types, such as human
hematopoietic progenitor cells, that were not efficiently
transduced by any of the ten different serotypes. It is
possible that the lack of measured transduction in these
cell types is because the CMV promoter is relatively
weak in these cells. It is not likely, however, that in these
cases the cells were overloaded with uptake and process-
ing of virions because when a 10-fold lower MOI was
used, lower transduction efficiency was seen in every
case (data not shown). Although, different growth condi-
tions were used for many of the different cell types, each
serotype was used for each cell type in the same condi-
tions, thus providing an internal control for a compara-
tive analysis. However, because a small amount of our
data does not perfectly match with previous findings, we
suggest that the results presented here should lead in-
vestigators to choose a few of the best serotypes for their
specific need. Our results demonstrate that there is no
simple mechanism to predict which serotype will trans-
duce a particular cell type but does suggest that if one
were limited to screening a small number of serotypes
that focusing on AAV6, AAV2, and AAV3 would be rea-
sonable as those three serotypes give a broad range of ef-
fectiveness across most cell types. In the future, it may
be important to further study the transduction of AAV
after different purification strategies are used, as it has
been shown to affect transduction [48]. Methods to fa-
cilitate AAV transduction, such as by the use of prote-
asome inhibitors [49] or strategies that allow for
selection of novel capsids, may help overcome the bar-
rier to transduction that these cells exhibit. However, it
is likely, there are factors, unproven as of yet, that serve
as major barriers to transduction by AAV. For example,
it is possible that the apparent low transduction could
be a consequence of AAV vectors inducing apopto-
sis [50]. In this case, a caspase inhibitor such as
Z-VAD-FMK could be used to achieve transduction
without cell death. Understanding these unproven bar-
riers to transduction would further improve the utility of
AAV as a gene transfer vector for ex vivo manipulation
of primary cells as well as in vivo gene therapy.
In summary, we have performed a survey of the ability
of different AAV serotypes to transduce a wide variety of
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survey should be a useful and practical resource for
investigators as they consider using AAV as a gene trans-
fer vector in their studies.
Methods
Ethics statement
All animal work has been conducted according to rele-
vant national and international guidelines. Approval for
studies using cells derived from mice was obtained from
the UT Southwestern IACUC, APB# 2010-0106.
AAV production
We thank R.J. Samulski for providing the self-
complementary eGFP and the pXR series of plasmids
used herein. AAV vector production relied on the triple
transfection method described previously [51]. Briefly, cells
were transfected with the adenovirus helper plasmid
pXX680, pHpa-Trs-SK CMV-eGFP (to generate self-
complementary AAV genomes) [5], a plasmid that codes
for AAV Rep2, and a specific capsid serotype (pXR series
1-9, corresponding to AAV serotypes 1-9). Three days after
HEK 293 cell transfection in a plate format, nuclei were
harvested, disrupted, and the lysate was separated by
cesium chloride gradient centrifugation [51]. DNase was
used during purification. Following an overnight spin at
55,000 rpm, 12 gradient fractions were pulled. To deter-
mine the gradient fraction composed of pure scAAV ge-
nomes, 10 μL of each fraction was subjected to Southern
blotting following alkaline gel electrophoresis as previously
described [51]. Fractions containing only scAAV genomes
were pooled, dialyzed against 1X PBS, aliquoted and stored
at -80 °C until use. Final titer determination was performed
after the initial thaw by quantitative PCR using primers
specific for the eGFP transgene (forward primer:
50-AGCAGCACGACTTCTTCAAGTC -30; reverse primer:
50-TGTAGTTGTACTCCAGCTTGTGCC-30).
Human primary cell isolation and culture conditions
BJ fibroblasts and BJ hTERT fibroblasts were a generous
gift from Jerry Shay and Woodring Wright and were cul-
tured as previously described [52]. The hES cell line H9
(WA09, XX, Passage 30-35) was cultured on feeder-
free fibronectin coated plates with mouse embryonic
fibroblast (MEF) conditioned human ES cell medium.
MEFs were mitomycin-c inactivated and plated in fibro-
blast medium, Dulbecco’s Modified Eagle Medium
(DMEM) (Invitrogen), supplemented with 10% bovine
growth serum (Hyclone, Logan, UT), 2 mM L-glutamine,
100 IU/mL penicillin, and 100 mg/ml streptomycin. 24 -
hours after attachment, the medium was replaced with
hES complete medium (77% DMEM:F12 (Sigma), 20%
Knockout SR (Invitrogen), 1% Non-Essential amino a-
cids (Invitrogen), 1% Penicillin/Streptomycin (Invitro-gen), 1 mM L-Glutamine (Invitrogen), 0.1 mM beta-
mercaptoethanol (Sigma), 4 ng/ml basic Fibroblast Growth
Factor (Invitrogen). After 24 hours, the medium was
removed, filtered, and used as conditioned medium for
human ES cell cultures. Cells were cultured in 5% CO2 at
37°C and passaged every 5-6 days to maintain undifferenti-
ated cultures. HUVEC cells (Lonza) were a generous gift
from Chieko Mineo and Phil Shaul (University of Texas
Southwestern Medical Center in Dallas (UTSW)) and were
cultured in Endothelial Cell Growth Medium-2 (EGM-2)
(Lonza) with the EGM-2 BulletKit (Lonza). Keratinocytes
(Invitrogen) were cultured in Keratinocyte Serum Free
Media (KSFM) + supplement (Invitrogen). The hema-
topoietic progenitor cells (Lonza) were isolated by CD34+
purification from bone marrow and were cultured in
hematopoietic progenitor cell medium (Lonza).
Human cell lines culture conditions
CaCo-2 cells were a generous gift from Jerry Shay and
Woodring Wright (UTSW) and were cultured in DMEM
(Media Tech) supplemented with 10% bovine growth
serum (Hyclone, Logan, UT), 2 mML-glutamine, 100 IU/
mL penicillin, and 100 mg/ml streptomycin. The cultures
were grown in a humidified incubator at 37°C with 5%
CO2. HBEC3KT cells were a generous gift from John
Minna (UTSW) and were cultured as previously described
[53]. HeLa cells were cultured in HepG2 cells (ATCC) were
cultured in the same way as CaCo-2 cells. HT-29 cells were
a generous gift from Jerry Shay and Woodring Wright
(UTSW) and were cultured in the same way as CaCo-2
cells. Jurkat cells were a generous gift from Zhijian Chen
(UTSW) and were cultured in Roswell Park Memorial In-
stitute 1640 (RPMI) (Media Tech) supplemented with 10%
bovine growth serum (Hyclone, Logan, UT), 2 mML-
glutamine, 100 IU/mL penicillin, and 100 mg/ml strepto-
mycin. The cultures were grown in a humidified incubator
at 37°C with 5% CO2. K562 (ATCC) cells were cultured in
the same way as Jurkat cells. MCF-7 cells were a generous
gift from Rolf Brekken (UTSW) and were cultured in the
same way as CaCo-2 cells. TF1α cells were a generous gift
from Saswati Chatterjee (City of Hope) and were cultured
in the same way as Jurkat cells. Saos-2 cells (ATCC) were
cultured in the same way as CaCo-2 cells. U2OS cells were
a generous gift from David Spector (Cold Spring Harbor)
and were cultured in the same way as CaCo-2 cells.
Mouse primary cell isolation and culture conditions
Adult skin fibroblasts, astrocytes, ES cells, and embry-
onic fibroblasts were isolated and cultured as described
previously [54]. The hematopoietic progenitor cells were
isolated from six to eight week old mice. Mice were
sacrificed and whole bone marrow was flushed from fe-
murs and tibias with IMDM 2% FBS. Next whole bone
marrow cells were spun down and resuspended in
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bone marrow by using MACS magnetic bead separation
with CD117+ microbeads (Miltenyi), running cells over
a MACs MS + column (Miltenyi), and washing the
column three times with MACS buffer. The column was
then removed from the magnetic field and cells retained
in the column were flushed with MACS buffer using a
plunger. The CD117+ were then washed and labeled with
antibodies to further enrich for long-term repopulating
cells using the following antibodies: non-specific binding
of antibodies was blocked by incubating cells with
a CD16/32 antibody (eBioscience), followed by labeling
cells with Lin- antibodies FITC-CD3e (eBioscience), FITC-
CD4 (eBioscience), FITC-CD5 (eBioscience), FITC-CD8a
(eBioscience), FITC-CD11b (eBioscience), FITC-CD45R
(eBioscience), FITC-Ly-6 G (eBioscience), FITC-Ter119
(eBioscience). An APC-Sca-1 (eBioscience) antibody was
used to label Sca-1+ cells. FITC-/ APC + cells (KLS cells)
were sorted using a FACsAria flow cytometer (BD Bio-
science) and cultured in Stemspan (Stemcell Technolo-
gies). Murine keratinocytes were isolated and cultured
as described previously [55]. The mesenchymal stem
cells were isolated and expanded from 8 week old mice
as previously described [56]. Briefly, whole bone mar-
row was flushed from femurs and tibias and plated in
Mesencult Proliferation kit media (Stemcell Technolo-
gies) in six well plates at a density of 5E6 cells per
mL and cultured as described previously. The skeletal
muscle progenitor cells were isolated and cultured as
described previously [57] (instruction in the isolation
method was generously provided by Amy Wagers at
Harvard University). The white adipose progenitor cells
were isolated and cultured as described previously
[58] (isolation instruction was generously provided by
Jon Graff at UTSW).
Mouse, hamster, and monkey cell lines culture conditions
3 T3 cells were created as previously described [54] and
were cultured in the same way as CaCo-2 cells. C2C12
cells were a generous gift from Eric Olson (UTSW) and
were cultured in the same way as CaCo-2 cells. MIN6
cells were a generous gift from Melanie Cobb (UTSW)
and were cultured as described previously [59]. CHO
cells were a generous gift from Ben Chen (UTSW) and
were cultured in the same way as CaCo-2 cells. COS-7
cells were a generous gift from Carole Mendelson (UTSW)
and were cultured in the same way as CaCo-2 cells.
AAV infection and measurement of GFP positive cells
Experiments for all cell types were performed in this man-
ner, unless otherwise noted. About 10,000 cells per well
were plated in 500 μL of media in a 24-well plate. Immedi-
ately after plating, the cells were infected with 1 of the 9
AAV serotypes at a multiplicity of infection (MOI) of100,000 viral genomes per cell (the experiments were re-
peated using an MOI of 10,000, not shown). At 24 hours,
an additional 0.5 mL of media was added to cells (for the
cells in a 24 well plate, otherwise the volume was doubled
from the original volume). At 48 hours post infection, the
cells were harvested and analyzed for GFP expression on a
FACS Caliber (Becton-Dickerson, San Jose, CA). For hES
cells, AAV transduction experiments were performed 2 days
after passage at a time when hES cell colonies were isolated
and predominantly monolayers. For murine hematopoietic
progenitor cells and murine mesenchymal stem cells, cells
were plated at 10,000 cells per well in a 96 well plate and
infected, as described above. For white fat progenitor cells,
cells were plated at 10,000 cells per well in a 48 well plate
and infected as described above. For murine keratinocytes,
cells were plated at 20,000 cells per well in a 48 well plate
and infected as described above. For murine skeletal muscle
progenitors, cells were plated at 2,500 cells per well in a 96
well plate and infected as described above.
Many of the experiments at an MOI of 100,000 were
done once, some were done two or three times. Experi-
ments were then repeated at an MOI of 10,000 and the
trends were the same (although, as expected, the %GFP
were lower). Thus, quantitative values of transduction
efficiencies of these serotypes cannot be determined by
this data. However, because only one preparation of each
serotype was used for all experiments for consistency
(and aliquoted and frozen at -80°C), this qualitative data
can be used to choose the best serotype(s) for transduc-
tion of a particular cell type. Furthermore, the preps of
virus made for this survey were first evaluated on 293
cells to ensure that transduction efficiency was compar-
able to the countless other preps that have been made of
these serotypes.
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